Combioxin

Combioxin is dedicated to revolutionizing the treatment of severe infections and immune dysfunction in intensive care. Its core technology uses proprietary engineered liposomes to capture and neutralize bacterial toxins, offering a novel mechanism against both Gram-positive and Gram-negative pathogens. The company has achieved significant regulatory milestones for CAL02, initiated a global Phase 2b study, and secured a worldwide out-licensing agreement with Eagle Pharmaceuticals, positioning it to address a critical unmet medical need with high mortality and cost.

Proprietary engineered liposomes designed to capture and neutralize bacterial virulence factors (toxins), offering a broad-spectrum, anti-virulence mechanism of action applicable to severe infections and immune dysfunction.

For CAL02, competition includes late-stage antibiotics and failed sepsis immunomodulators; differentiation lies in its broad-spectrum, anti-virulence mechanism. In immunoparalysis, there are virtually no direct competitors, positioning Combioxin as a pioneer. The partnership with Eagle Pharmaceuticals provides a commercial advantage.